26.57

3.31% -0.91

After Hours: 26.57

Zymeworks Inc. (ZYME)

Overview News Price History Option Chain Discussions Forecast

Zymeworks Inc. stock is traded at $26.57, with a volume of 940.38K. It is down -3.31% in the last 24 hours and up +1.92% over the past month. Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Previous Close:

$27.48

Open:

$27.45

24h Volume:

940.38K

Relative Volume:

1.57

Market Cap:

$1.90B

Revenue:

$81.26M

Net Income/Loss:

$-102.66M

P/E Ratio:

-19.43

EPS:

-1.3678

Net Cash Flow:

$-77.62M

1W Performance:

+1.26%

1M Performance:

+1.92%

6M Performance:

+13.30%

1Y Performance:

+61.13%

1-Day Range:

$26.38

$27.55

1-Week Range:

$25.81

$27.86

52-Week Range:

$15.81

$31.34

Zymeworks Inc. Stock (ZYME) Company Profile

Name

Zymeworks Inc.

Sector

Healthcare (1065)

Industry

Biotechnology (594)

Phone

604-678-1388

Address

1385 West 8th Avenue, Suite 540, Vancouver, BC

Employee

170

Twitter

@ZymeworksInc

Next Earnings Date

2026-11-05

Latest SEC Filings

ZYME's Discussions on Twitter

Compare ZYME vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZYME Zymeworks Inc.	26.57	1.88B	81.26M	-102.66M	-77.62M	-1.3678
VRTX Vertex Pharmaceuticals Inc	508.34	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	784.85	80.46B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	990.32	61.58B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	154.04	57.48B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	190.95	43.68B	742.00K	-1.37B	-1.07B	-7.0731

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-03-25	Initiated	Citizens JMP	Mkt Outperform
Oct-24-25	Resumed	Wells Fargo	Equal Weight
Oct-14-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-10-25	Initiated	B. Riley Securities	Buy
May-20-25	Initiated	TD Cowen	Buy
Dec-16-24	Upgrade	JP Morgan	Neutral → Overweight
Nov-07-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-01-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-21-23	Resumed	Wells Fargo	Overweight
Jan-04-23	Reiterated	H.C. Wainwright	Neutral
Dec-20-22	Upgrade	Jefferies	Hold → Buy
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-04-22	Resumed	Wells Fargo	Overweight
May-05-22	Upgrade	Guggenheim	Neutral → Buy
Mar-15-22	Initiated	Evercore ISI	Outperform
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold
Mar-31-21	Initiated	Credit Suisse	Outperform
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Feb-08-21	Resumed	H.C. Wainwright	Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-06-20	Initiated	SVB Leerink	Outperform
Jan-10-20	Initiated	Wolfe Research	Outperform
Dec-09-19	Initiated	JP Morgan	Neutral
Nov-25-19	Initiated	H.C. Wainwright	Buy
Nov-20-19	Initiated	Guggenheim	Buy
Sep-30-19	Upgrade	Raymond James	Outperform → Strong Buy
Aug-30-19	Initiated	Stifel	Buy
Jul-18-19	Initiated	Deutsche Bank	Buy
May-11-18	Upgrade	Barclays	Underweight → Equal Weight
Mar-19-18	Initiated	Raymond James	Outperform

View All

Zymeworks Inc. Stock (ZYME) Latest News

Sep 12, 2026

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME - MarketBeat

Sep 12, 2026

Sep 11, 2026

Wellington Management Group LLP Takes $2.88 Million Position in Zymeworks Inc. $ZYME - MarketBeat

Sep 11, 2026

Sep 08, 2026

Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME - MarketBeat

Sep 08, 2026

Sep 07, 2026

Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME - MarketBeat

Sep 07, 2026

Sep 03, 2026

JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00 - MarketBeat

Sep 03, 2026

Sep 02, 2026

Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighTime to Buy? - MarketBeat

Sep 02, 2026

Zymeworks stock hits 52-week high at 30.75 USD - Investing.com

Sep 02, 2026

Zymeworks stock hits 52-week high at 30.75 USD By Investing.com - Investing.com Nigeria

Sep 02, 2026

Aug 31, 2026

ZJM stock holds near its latest trade. Zymeworks data still drives the setup - ad-hoc-news.de

Aug 31, 2026

Aug 30, 2026

Enterprise value to revenue forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView

Aug 30, 2026

Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME - marketbeat.com

Aug 30, 2026

4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc. - marketbeat.com

Aug 30, 2026

Aug 29, 2026

Zymeworks stock holds near $28.27 as market cap tops $2.01 billion - ad-hoc-news.de

Aug 29, 2026

Aug 28, 2026

Zymeworks moves higher as Street cheers Ziihera regimen approval - Seeking Alpha

Aug 26, 2026

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens - Sahm

Aug 26, 2026

Zymeworks stock hits 52-week high at 29.81 USD By Investing.com - Investing.com South Africa

Aug 26, 2026

Zymeworks stock rating reiterated at Market Outperform by Citizens - Investing.com India

Aug 26, 2026

Zymeworks (ZYME) Secures FDA Approval And $250 Million Milestone, Is The Stock Still Undervalued? - sahmcapital.com

Aug 26, 2026

Aug 25, 2026

Zymeworks Announces FDA Approval of Ziihera-Based Regimens for First-Line HER2-Positive Gastroesophageal Adenocarcinoma and $250 Million Milestone Payment from Jazz Pharmaceuticals - quiverquant.com

Aug 25, 2026

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma - NTB Kommunikasjon

Aug 25, 2026

Aug 24, 2026

Deutsche Bank AG Buys Shares of 397,190 Zymeworks Inc. $ZYME - MarketBeat

Aug 24, 2026

Aug 21, 2026

Theravance (NASDAQ: TBPH) sets vote on cash buyout with ampreloxetine CVR upside - Stock Titan

Aug 21, 2026

Aug 18, 2026

Enterprise value to revenue forward of Zymeworks Inc. – SWB:ZA8 - TradingView

Aug 18, 2026

Zymeworks (ZYME) Session Brief: Climbs 2.69% to $25.99 in the Latest Session; Reference Levels: $24.69 and $27.29 Define the Nearby Reference Levels at the ClosePCR Spike - vinanet.vn

Aug 18, 2026

Aug 17, 2026

How Zymeworks’ Bigger Loss, Buyback and Milestones Pivot At Zymeworks (ZYME) Has Changed Its Investment Story - simplywall.st

Aug 17, 2026

Aug 15, 2026

ZYME Q2 2026 Earnings: Wider-than-Expected Loss of -$0.62 per Share Reflects Clinical-Stage InvestmentProduct Revenue Analysis - vinanet.vn

Aug 15, 2026

Aug 12, 2026